

BIOMARK DIAGNOSTICS INC.

CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

December 31, 2015

(Stated in Canadian Dollars)

(Unaudited – Prepared by Management)

NOTICE OF NO AUDITOR REVIEW OF CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

Under National Instrument 51-102, if an auditor has not performed a review of the condensed consolidated interim financial statements, they must be accompanied by a notice indicating that the condensed consolidated interim financial statements have not been reviewed by an auditor.

The accompanying unaudited condensed consolidated interim financial statements have been prepared by and are the responsibility of the Company's management.

The Company's independent auditor has not performed a review of these condensed consolidated interim financial statements in accordance with standards established by the Canadian Institute of Chartered Accountants for review of condensed consolidated interim financial statements by an entity's auditor.

BIOMARK DIAGNOSTICS INC.
CONDENSED CONSOLIDATED INTERIM STATEMENTS OF FINANCIAL POSITION
(Stated in Canadian Dollars)
(Unaudited – Prepared by Management)

	Note	December 31, 2015 (Unaudited)	March 31, 2015 (Audited)
		\$	\$
ASSETS			
Current			
Cash		3,962	196,235
Accounts receivable		4,589	4,589
GST receivable		34,272	26,286
Prepaid		1,641	3,225
		44,464	230,335
LIABILITIES			
Current			
Accounts payable and accrued liabilities		217,834	47,293
Due to a related party	4	335,673	35,081
		553,507	82,374
SHAREHOLDERS' DEFICIENCY			
Share capital	5	2,520,762	2,420,072
Share subscriptions	5	-	100,000
Contributed surplus	5	562,803	518,127
Deficit		(3,592,609)	(2,890,238)
		(509,043)	147,961
		44,464	230,335

Nature and Operations and Going Concern (Note 1)
Subsequent Event (Note 9)
Commitment (Note 10)

Approved by the Board on February 24, 2015

“Rashid Ahmed”

BIOMARK DIAGNOSTICS INC.**CONDENSED CONSOLIDATED INTERIM STATEMENTS OF COMPREHENSIVE LOSS**

(Stated in Canadian Dollars)

(Unaudited – Prepared by Management)

	Note	Three Months Ended		Nine Months Ended	
		December 31, 2015	December 31, 2014	December 31, 2015	December 31, 2014
Revenue:		\$ -	\$ 9,200	\$ 4,410	\$ 9,200
Expenses:					
Corporate and professional services		80,141	155,385	244,407	170,947
Listing fees		-	1,243,050	-	1,245,720
Legal fees		27,010	82,418	98,342	172,080
Office and miscellaneous		34,369	94,597	61,068	105,108
Research and other		110,009	174,569	258,288	174,569
Share-based compensation	5	9,363	222,032	44,676	222,032
Wages and benefits		-	87,788	-	87,788
		260,892	2,059,839	706,381	2,178,244
Net loss and comprehensive loss for the period		(260,892)	(2,050,639)	(702,371)	(2,169,044)
Basic and diluted loss per share		(0.005)	(0.07)	(0.014)	(0.15)
Weighted average number of common shares outstanding		49,403,416	31,388,559	49,284,592	14,814,243

BIOMARK DIAGNOSTICS INC.
CONDENSED CONSOLIDATED INTERIM STATEMENTS OF CASH FLOWS
For the third quarter ended December 31, 2015
(Stated in Canadian Dollars)
(Unaudited – Prepared by Management)

	Nine Months Ended	
	December 31, 2015	December 31, 2014
	\$	\$
Operating Activities		
Net loss for the period	(702,371)	(2,169,044)
Listings expense	-	1,210,204
Stock-based compensation	44,676	222,032
	(657,695)	(736,808)
Changes in non-cash working capital item related to operations:		
Accounts receivable	-	(9,200)
GST receivable	(7,986)	(13,678)
Prepaid	1,584	-
Accounts payable and accrued liabilities	170,541	34,735
	(493,556)	(724,951)
Cash used in operating activities		
Financing Activities		
Due to a related party	300,593	114,091
Commitment to issue shares	-	114,500
Share issued for cash	-	523,260
Issue of common shares, net of issuance costs	690	-
	301,283	752,151
Cash provided by financing activities		
Decrease in cash during the period	(192,273)	27,200
Cash, beginning of the period	196,235	92,000
Cash, end of the period	3,962	119,200
Supplemental Disclosure of Cash Flow Information:		
Cash paid during the period:		
Interest	-	-
Income taxes	-	-

Non-cash Transactions – see Note 8

BIOMARK DIAGNOSTICS INC.
CONDENSED CONSOLIDATED INTERIM STATEMENTS OF CHANGES IN SHAREHOLDERS' DEFICIENCY
For the period ended December 31, 2015
(Stated in Canadian Dollars)
(Unaudited – Prepared by Management)

	<u>Number of Shares</u>	<u>Share Capital</u> \$	<u>Commitment to Issue Shares</u> \$	<u>Contributed Surplus</u> \$	<u>Deficit</u> \$	<u>Total</u> \$
Balance, June 19, 2014 (date of incorporation)	-	-	-	-	-	-
Shares issued for cash at \$0.001	10,000	1	-	-	-	1
Shares cancelled	(10,000)	(1)	-	-	-	(1)
Shares exchanged by Biomark Cancer shareholders	44,900,000	1,225,000	-	34,704	-	1,259,704
Shares issued to Noor Energy Corporation	310,000	62,500	-	-	-	62,500
Shares issued for cash	2,125,040	531,260	-	-	-	531,260
Share issue costs	-	(17,700)	-	-	-	(17,700)
Share received for private placement	-	-	114,500	-	-	114,500
Stock-based compensation	-	-	-	222,032	-	222,032
Comprehensive loss	-	-	-	-	(2,184,126)	(2,184,126)
Balance, December 31, 2014	47,335,040	1,801,060	114,500	256,736	(2,184,126)	(11,830)

	<u>Number of Shares</u>	<u>Share Capital</u> \$	<u>Share Subscriptions</u> \$	<u>Contributed Surplus</u> \$	<u>Deficit</u> \$	<u>Total</u> \$
Balance, March 31, 2015	48,635,040	2,420,072	100,000	518,127	(2,890,238)	147,961
Shares issued under private placement	200,000	100,000	-	-	-	100,000
Shares cancelled	(21,624)	(10,812)	-	-	-	(10,812)
Shares issued for cash	590,000	11,502	-	-	-	11,502
Share subscription received	-	-	(100,000)	-	-	(100,000)
Stock-based compensation	-	-	-	44,676	-	44,676
Comprehensive loss	-	-	-	-	(702,371)	(702,371)
Balance, December 31, 2015	49,403,416	2,520,762	-	562,803	(3,592,609)	(509,043)

THE ACCOMPANYING NOTES ARE AN INTEGRAL PART OF THESE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

BIOMARK DIAGNOSTICS INC.

Notes to the Condensed Consolidated Interim Financial Statements

December 31, 2015

(Stated in Canadian Dollars)

(Unaudited – Prepared by Management)

1. Nature and Operations and Going Concern

BioMark Diagnostics Inc. (“BioMark Diagnostics” or the “Company”) was incorporated on June 19, 2014 under the Business Corporation Act of British Columbia. The head office of the Company is 165 – 10551 Shellbridge Way, Richmond, British Columbia, V6X 2W8. The ultimate parent of BioMark Diagnostics is BioMark Technologies Inc. (“BioMark Technologies”), which is located at the same address as the Company.

Asset Purchase Agreement

On September 5, 2014 and amended on September 8 and 18, 2014, Luger Minerals Corp. (“Luger”) entered into an agreement (the “Asset Purchase Agreement”) with Biomark Technologies, Rashid Ahmed Bux (“Rashid”) and Bux Investments Ltd. (“Bux”) to acquire and transfer certain assets, properties and rights (collectively “IP”) to Luger for the following consideration:

- i) Issuance of 40,000,000 common shares of Luger to Biomark Technologies (issued on September 29, 2014);
- ii) Loan forgiveness of the balance due from Biomark Technologies; and
- iii) Assumption of all expenses incurred by Biomark Technologies for this transaction

Plan of Arrangement

During the prior year, the Company entered into an Arrangement Agreement (“Arrangement”) with Luger, Noor Energy Corporation (“Noor”) and Kyle Stevenson, the controlling shareholder of Noor (the “Controlling Shareholder”). Under the Arrangement, the following transactions took place on October 30, 2014:

- i) Luger acquired from Noor, which is a company listed on the Canadian Stock Exchange (“CSE”), all of the issued and outstanding shares of Noor’s wholly owned subsidiary, BioMark Diagnostics (the “Purchase Shares”), for consideration of \$5,000.
- ii) Each outstanding Luger common share was then exchanged for one BioMark Diagnostics common share, such that Luger became a wholly-owned subsidiary of BioMark Diagnostics.
- iii) Noor issued 1,000 of its common shares to BioMark Diagnostics in exchange for 370,000 common shares of BioMark Diagnostics. Out of the 370,000 shares, the Controlling Shareholder of Noor agreed to forgo 60,000 common shares, which were cancelled in October 2014.

Following the completion of the Arrangement, BioMark Diagnostics applied for a listing on the CSE. On November 3, 2014, the Company commenced trading on the CSE under the trade symbol “BUX”.

BIOMARK DIAGNOSTICS INC.

Notes to the Condensed Consolidated Interim Financial Statements

December 31, 2015

(Stated in Canadian Dollars)

(Unaudited – Prepared by Management) – Page 2

1. Nature and Operations and Going Concern (continued)

As a result of the above noted transactions, the parties who controlled the IP before the Asset Purchase Agreement and the Arrangement continued to control Biomark Diagnostics Inc., including the IP. The historical costs of the IP were not identifiable or recognized prior to these transactions. As a result, no value has been allocated to the 40,000,000 shares issued to Biomark Technologies under the Asset Purchase Agreement. The resulting financial statements are presented as a continuance of Luger and comparative figures presented in the financial statements after the Arrangement are those of Luger.

On October 15, 2014, Luger, now the wholly-owned subsidiary of BioMark Diagnostics Inc. changed its name to BioMark Cancer Systems Inc. (“BioMark Cancer”).

Concurrent with the closing of the Arrangement, the Company and Biomark Technologies entered into an agreement (the “Stock Restriction Agreement”) restricting the transfer of 40,000,000 common shares of the Company, being those issued in connection with the Asset Purchase Agreement. These shares are subject to a 36-month release period commencing November 3, 2014 (the “Listing Date”), with 10% released upon the Listing Date and 15% of such shares released in 6-month intervals thereafter. As at December 31, 2015, there were 24,000,000 common shares held in escrow.

2. Basis of Preparation

Statement of Compliance

These condensed consolidated interim financial statements, including comparatives, have been prepared in accordance with International Financial Reporting Standards (“IFRS”) as issued by the International Accounting Standards Board (“IASB”), Interpretations issued by the International Financial Reporting Interpretations Committee (“IFRIC”) and in accordance with International Accounting Standard (“IAS”) 34 Interim Financial Reporting and which were in effect as of December 31, 2015.

Basis of Measurement and Consolidation

The condensed consolidated financial statements have been prepared on an accrual basis and are based on historical costs. The consolidated financial statements are presented in Canadian dollars which is also the Company’s functional currency.

These condensed consolidated financial statements have been prepared on a going concern basis, which assumes that the Company will be able to realize its assets and discharge its liabilities in the normal course of business. As at December 31, 2015, the Company has an accumulated deficit of \$3,592,609. The continued operations of the Company are dependent on its ability to generate future cash flows or obtain additional financing. Management is of the opinion that sufficient working capital will be obtained from external financing to meet the Company’s liabilities and commitments as they become due, although there is a risk that additional financing will not be available on a timely basis or on terms acceptable to the Company. These condensed consolidated financial statements do not reflect any adjustments that may be necessary if the Company is unable to continue as a going concern. These conditions indicate the existence of a material uncertainty that may cast significant doubt on the Company’s ability to continue as a going concern.

These condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiary, BioMark Cancer. BioMark Cancer was incorporated on February 27, 2014 under the Business Corporation Act of British Columbia. All material inter-company balances and transactions have been eliminated upon consolidation.

BIOMARK DIAGNOSTICS INC.
Notes to the Condensed Consolidated Interim Financial Statements
December 31, 2015
(Stated in Canadian Dollars)
(Unaudited – Prepared by Management) – Page 3

2. Basis of Preparation (continued)

Significant Estimates and Assumptions

The preparation of condensed consolidated financial statements in accordance with IFRS requires the Company to make estimates and assumptions concerning the future. The Company's management reviews these estimates and underlying assumptions on an ongoing basis, based on experience and other factors,

including expectations of future events that are believed to be reasonable under the circumstances. Revisions to estimates are adjusted for prospectively in the period in which the estimates are revised.

Estimates and assumptions where there is significant risk of material adjustments to assets and liabilities in future accounting periods include the fair value measurements for financial instruments and the recoverability and measurement of deferred tax assets.

Significant Judgements

The preparation of condensed consolidated financial statements in accordance with IFRS requires the Company to make judgments, apart from those involving estimates, in applying accounting policies. The most significant judgments in applying the Company's financial statements are the valuation of shares in the listing expense, the classification of financial instruments and the going concern assumption.

In addition, management has made certain estimates and assumptions when calculating the fair value of share options. The significant assumptions include estimates of expected volatility, expected life and expected risk-free rate of return. Management also makes certain assumptions with respect to the number of options expected to vest. Changes in these assumptions may result in a material change to share-based compensation expense.

3. Significant Accounting Policies

The preparation of financial data is based on accounting principles and practices consistent with those used in the preparation of the audited financial statements of BioMark Cancer as at March 31, 2015. The accompanying unaudited condensed consolidated interim financial statements should be read in conjunction with the BioMark Cancer's audited financial statements for the period ended March 31, 2015.

Intellectual properties

Intellectual properties consist of patents and trademarks acquired from BioMark Technologies. Research costs are expensed as incurred. Development costs are expensed as incurred unless they meet certain criteria for deferral and amortization. The Company assesses whether it has met the relevant criteria for deferral and amortization at each reporting date.

Stock-based compensation:

Stock options granted to employees, consultants or directors are measured at fair value at the grant date and expensed over the vesting period with a corresponding increase to contributed surplus. Upon the exercise of the stock options, consideration paid together with the amount previously recognized in contributed surplus is recorded as an increase to share capital.

Impairment of tangible and intangible assets

At the end of each reporting period, the Company's assets are reviewed to determine whether there is any indication that those assets may be impaired. If such indication exists, the recoverable amount of the asset is estimated in order to determine the extent of the impairment, if any. The recoverable amount is the higher of

BIOMARK DIAGNOSTICS INC.

Notes to the Condensed Consolidated Interim Financial Statements

December 31, 2015

(Stated in Canadian Dollars)

(Unaudited – Prepared by Management) – Page 4

3. Significant Accounting Policies (cont'd)

fair value less costs to sell and value in use. Fair value is determined as the amount that would be obtained from the sale of the asset in an arm's length transaction between knowledgeable and willing parties. In assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset. If the recoverable amount of an asset is estimated to be less than its carrying amount, the carrying amount of the asset is reduced to its recoverable amount and the impairment loss is recognized in profit or

loss for the period. For an asset that does not generate largely independent cash flows, the recoverable amount is determined for the cash generating unit to which the asset belongs.

Where an impairment loss subsequently reverses, the carrying amount of the asset (or cash-generating unit) is increased to the revised estimate of its recoverable amount, but to an amount that does not exceed the carrying amount that would have been determined had no impairment loss been recognized for the asset (or cash-generating unit) in prior years. A reversal of an impairment loss is recognized immediately in profit or loss.

Accounting standards issued but not yet applied

The following new standards and interpretations are not yet effective and have not been applied in preparing these financial statements. The Company is currently evaluating the potential impacts of these new standards and does not anticipate any material changes to the financial statements upon adoption of this new and revised accounting pronouncement.

- IFRS 9 – *Financial Instruments* (effective January 1, 2018) introduces new requirements for the classification and measurement of financial assets, and will replace IAS 39. IFRS 9 uses a single approach to determine whether a financial asset is measured at amortized cost or fair value, replacing the multiple classification options available in IAS 39.

4. Due to a related party

During the period ended December 31, 2015, the Company has the following transactions with BioMark Technologies:

	\$
Balance, March 31, 2015	\$35,081
Company expenses paid by BioMark Technologies to date	242,092
Money transfer from BioMark Technologies – December 31, 2015	58,500
Cash payments to BioMark Technologies – December 31, 2015	-
<u>Balance payable, December 31, 2015</u>	<u>335,673</u>

The expenses paid by BioMark Technologies represent the expenses incurred per General Service Agreement as indicated in Note 4, in the amount of \$238,021 plus the applicable taxes of \$4,071.

On May 14, 2014, the Company entered into an Independent Contractor Agreement (the "CEO Agreement") with the CEO of the Company. According to the Agreement, the CEO will provide consulting services to the Company for one year with a compensation of \$240,000 per year plus benefits. In addition, the CEO will be paid a cash bonus equivalent to 30% of the annual salary at the end of each year if the trading price of the Company shares increased by more than 30% from the trading price at the beginning of the year. For the purpose of this calculation, the starting trading price is \$0.25 per share. The CEO will also be granted stock options for 1,000,000 common shares of the Company at a price of \$0.25 per share (granted). Finally, if the

BIOMARK DIAGNOSTICS INC.

Notes to the Condensed Consolidated Interim Financial Statements

December 31, 2015

(Stated in Canadian Dollars)

(Unaudited – Prepared by Management) – Page 5

Company's market capitalization exceeds \$200 million USD, the CEO will be paid an additional cash bonus of \$500,000.

In addition, on May 14, 2014, the Company also entered a General Service Agreement (the "Service Agreement") with BioMark Technologies Inc., a company that holds approximately 82% of the common shares of the Company as at December 31, 2015. Both BioMark Diagnostics and BioMark Technologies are controlled by the CEO of the Company. According to the Service Agreement, the Company engaged BioMark Technologies to provide services of research and development, quality management, IP refinement, training, territorial business development, supplier review and related functions (the "Services"). The Company will pay management fees equivalent to cost plus a 25% administration fee to BioMark Technologies and payable upon completion of the Services. For any loan facility funded by BioMark Technologies, the Company will pay an 8% per annual interest. For the period ended December 31, 2015, the Company paid \$20,587 to BioMark Technologies as administration fees.

5. Share Capital

a) Authorized
Unlimited common shares, without par value.

b) Issued
Common shares issued and outstanding:

	Shares	Amount
		\$
Balance, March 31, 2015	48,635,040	2,420,072
Share issued under private placement	200,000	100,000
Shares cancelled	(21,624)	(10,812)
Shares issued to Caro and Regal	500,000	236
Shares issued to LHA	50,000	1,266
Shares issued for cash	40,000	10,000
Balance, December 31, 2015	49,403,416	2,520,762

c) Stock Options:

The Corporation has reserved 4,490,000 common shares under its 2014 Stock Option Plan. The plan provides for the granting of options to directors, employees and consultants. The Board of Directors determines the features of the awards, including the exercise price, the term and vesting provisions, provided no stock options will have a term exceeding five years.

On October 31, 2014, the Company granted 4,490,000 stock options to directors, officers, consultants, and employees. Stock options outstanding at December 31, 2015 will expire on October 31, 2019. Stock options granted to directors and officers of the Company (3,320,000 options) vest at 25% at the date of grant and 25% every six months thereafter. Stock options granted to consultants (1,170,000 options) vest at 33.33% every 6 months from the date of grant. As of December 31, 2015, there were 4,490,000 stock options outstanding and 3,270,000 stock options are vested and exercisable at \$0.25 per option. The weighted average life remaining for these options was 3.83 years and weighted average exercise price was \$0.25 per option.

BIOMARK DIAGNOSTICS INC.

Notes to the Condensed Consolidated Interim Financial Statements

December 31, 2015

(Stated in Canadian Dollars)

(Unaudited – Prepared by Management) – Page 6

5. Share Capital (cont'd)

The fair value of the share-based compensation from vested options recognized during the period ended December 31, 2015 was \$9,363. The Company used the Black-Scholes option pricing model with weighted average assumptions and resulting values for grants as follows:

	2015
Assumptions:	
Weighted average risk free interest rate (%)	1.46%
Expected life (years)	5.0 years
Weighted average expected volatility (%)	79%
Expected dividend	Nil

The weighted average fair value of each option granted was \$0.25 in 2015.

d) Warrants:

Information regarding the Company's outstanding warrants is summarized below:

	Expiry date	Number of warrants outstanding	Number of warrants exercisable	Exercise price
Balance, March 31, 2015	-	-	-	-
Granted	January 2, 2016	151,000	151,000	\$0.80
Granted	February 18, 2016	608,188	608,188	\$0.80
Balance December 31, 2015		759,188	759,188	\$0.80

The outstanding shareholder warrants at December 31, 2015 will expire in February 18, 2016.

e) Contributed Surplus:

	\$
Balance, March 31, 2015	518,127
Cancelled	-
Stock-based recovery – June 30, 2015	(16,040)
Stock-based compensation – September 30, 2015	51,353
Stock-based compensation – December 31, 2015	9,363
Balance December 31, 2015	562,803

6. Financial Instruments

The Company is exposed to varying degrees to a variety of financial instrument related risks:

Fair value

The carrying value of cash, accounts receivable, accounts payable and due to a related party approximated their fair value because of the relatively short-term nature of these instruments.

Credit risk

BIOMARK DIAGNOSTICS INC.

Notes to the Condensed Consolidated Interim Financial Statements

December 31, 2015

(Stated in Canadian Dollars)

(Unaudited – Prepared by Management) – Page 7

The Company is exposed to credit risk with respect to its accounts receivable. To reduce the credit risk of the loan receivable, the Company regularly reviews the collectability.

Interest rate risk

Interest rate risk is the risk the fair value or future cash flows of a financial instrument will fluctuate because of changes in market interest rates. Financial assets and liabilities with variable interest rates expose the Company to cash flow interest rate risk. The Company does not hold any financial liabilities with variable interest rates. The Company does maintain bank accounts which earn interest at variable rates but it does not believe it is currently subject to any significant interest rate risk.

Liquidity risk

The Company's ability to continue as a going concern is dependent on management's ability to raise required funding through future equity issuances and through short-term borrowing. The Company manages its liquidity risk by forecasting cash flows from operations and anticipating any investing and financing activities. Management and the Board of Directors are actively involved in the review, planning and approval of significant expenditures and commitments.

The Company intends to meet its current obligations in the following year with funds to be raised through private placements, shares for debt, loans and related party loans.

Fair value

Financial instruments measured at fair value are classified into one of three levels in the fair value hierarchy according to the relative reliability of the inputs used to estimate the fair values. The three levels of the fair value hierarchy are:

- Level 1 – Unadjusted quoted prices in active markets for identical assets or liabilities;
- Level 2 – Inputs other than quoted prices that are observable for the asset or liability either directly or indirectly; and
- Level 3 – Inputs that are not based on observable market data.

7. Capital Risk Management

The Company defines its capital as shareholders' equity. The Company's objectives when managing capital are to safeguard the Company's ability to continue as a going concern in order to pursue the development of its technologies and to maintain a flexible capital structure for its projects for the benefit of its shareholders. As the Company is in the development stage, its principal source of funds is from the issuance of common shares.

The Company manages the capital structure and makes adjustments to it in light of changes in economic conditions and the risk characteristics of the underlying assets. To maintain or adjust the capital structure, the Company may attempt to issue new shares, acquire or dispose of assets or adjust the amount of cash.

The Company is not subject to externally imposed capital requirements.

8. Non-cash Transactions

Investing and financing activities that do not have a direct impact on cash flows are excluded from the statements of cash flows. The following transactions were excluded from the statement of cash flows:

During the period ended December 31, 2015:

- The Company issued 50,000 common shares pursuant to the terms of the Agreement with LHA.

BIOMARK DIAGNOSTICS INC.

Notes to the Condensed Consolidated Interim Financial Statements

December 31, 2015

(Stated in Canadian Dollars)

(Unaudited – Prepared by Management) – Page 8

9. Subsequent Events

- a) On February 16, 2016, the Company announced that it has completed the internal standards for its assay to meet both Health Canada and FDA requirements for the 200 patient trial completed in Fall of 2015.

10. Commitment

- a) The Company is committed to an office lease for its office in Richmond, British Columbia expiring on October 2016. Minimum lease payments of \$25,962 annually are required until October 2016.
- b) On February 6, 2015, the Company entered into an agreement with Caro Capital LLC (“Caro”) and Regal Venture Capital Partners (“Regal”), Florida corporations, of which Caro and Regal will provide services for management consulting and public relations. The term of the agreement was six months. The Company is committed to issue 550,000 common shares. On April 20, 2015, the Company issued 500,000 common shares and on August 5, 2015, the Company issued 50,000 common shares.
- c) The Company is committed to the CEO Agreement with the CEO as described in Note 4.
- d) The Company is committed to a General Service Agreement with BioMark Technologies Inc. as described in Note 4.